Primecap Management Co. CA Has $182.08 Million Position in Glaukos Co. (NYSE:GKOS)

Primecap Management Co. CA lessened its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 2.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,214,325 shares of the medical instruments supplier's stock after selling 30,860 shares during the quarter. Primecap Management Co. CA owned 2.20% of Glaukos worth $182,076,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Wellington Management Group LLP boosted its stake in Glaukos by 294.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier's stock valued at $284,501,000 after buying an additional 1,630,270 shares in the last quarter. William Blair Investment Management LLC bought a new position in shares of Glaukos during the fourth quarter valued at $121,390,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Glaukos by 47.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier's stock valued at $83,609,000 after purchasing an additional 207,338 shares in the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Glaukos by 21.6% in the 3rd quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier's stock worth $87,776,000 after purchasing an additional 119,527 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Glaukos during the 4th quarter worth about $16,910,000. Institutional investors and hedge funds own 99.04% of the company's stock.

Remove Ads

Insiders Place Their Bets

In related news, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.40% of the company's stock.

Analysts Set New Price Targets

GKOS has been the topic of several research analyst reports. Wells Fargo & Company upped their price objective on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Stifel Nicolaus raised their price target on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, December 31st. Piper Sandler reissued an "overweight" rating and issued a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. BTIG Research raised their target price on Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, UBS Group assumed coverage on Glaukos in a report on Friday, December 6th. They issued a "buy" rating and a $182.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $163.25.

Glaukos Trading Up 1.4 %

Shares of GKOS traded up $1.39 on Friday, reaching $102.02. 1,040,792 shares of the company's stock were exchanged, compared to its average volume of 585,958. The business has a 50 day moving average price of $136.42 and a two-hundred day moving average price of $136.75. Glaukos Co. has a 12 month low of $86.74 and a 12 month high of $163.71. The stock has a market capitalization of $5.77 billion, a P/E ratio of -35.55 and a beta of 0.99. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.